Goldline Pharmaceutical IPO
Open SmeCurrent GMP
₹15 (+34.88%)
Price Band
₹ 41 – 43
Lot Size
3000
Issue Size
₹12 Cr
Minimum Investment
₹258000 (6000 Shares)
Listing Date
19 May 2026
Subscription
840.81x
About the Company
Goldline Pharma comprises 42 products catering to a wide range of medical specialties, including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. This division focuses on delivering quality formulations for acute and chronic healthcare requ
Go
Goldline Cardinal includes 54 products developed for the specialty healthcare segment. The division primarily serves Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, offering therapies focused on lifestyle
Goldline Aayushman
Goldline Aayushman consists of 18 products designed for Pediatricians, Child Specialists, Neonatologists, and General Practitioners. The division focuses on pediatric and neonatal healthcare solutions aimed at supporting child wellness and development.
Goldline InLife
Goldline InLife offers 22 products catering to Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. The division is focused on critical care and specialty treatments required in advanced healthcare settings and hospitals.
Goldline Wellness
Goldline Wellness comprises 10 products dedicated to supportive care in cancer therapy and patient wellness management. The division emphasizes improving patient care and quality of life during treatment.
The company follows an asset-light business model and does not manufacture pharmaceutical products directly. Instead, it collaborates with third-party manufacturers who produce medicines based on the company’s market research, product specifications, and quality standards, while ensuring compliance with applicable pharmaceutical regulations.
All products are marketed and sold under the “Goldline” brand through a well-established distribution network comprising distributors, retailers, and wholesalers. The company currently partners with 15 manufacturers and 7 distributors to ensure efficient supply chain management and market reach.
In addition to pharmaceutical marketing and distribution, the company also supports hospitals and healthcare institutions through procurement assistance and material supply services.
Goldline Pharmaceuticals has established its presence across multiple Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Promoters
- Amol Laxmikant Mujumdar
- Swapan Premprakash Khandelwal
Promoters Holding
Holding Pre Issue
79.70%
Holding Post Issue
0.00%
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
- General corporate purposes
Address / Contact Info
Goldline Pharmaceutical Ltd. Address
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Email: info@goldlinepharma.in
Tel: +91 712 278 6666
Website:http://www.goldlinepharma.in/
IPO Snapshot
IPO Timeline (Tentative)
IPO Open Date
Tuesday, 12 May 2026
IPO Close Date
Thursday, 14 May 2026
Basis of Allotment
Friday, 15 May 2026
Initiation of Refunds
Monday, 18 May 2026
Credit of Shares to Demat
Monday, 18 May 2026
Listing Date
Tuesday, 19 May 2026 — NSE & BSE
Important Dates
Open Date
12 May 2026
Close Date
14 May 2026
Basis Of Allotment
15 May 2026
Listing Date
19 May 2026
Financial Performance (₹ in Crores)
| Particular | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.4 | 26.28 | 22.93 | 19.39 |
| Revenue | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| Net Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserve & Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowings | 9.47 | 11.03 | 11.13 | 10.83 |
EPS Pre
4.11%
EPS Post
2.95%
P/E Pre
10.47
P/E (Post Issue)
14.56x
Company Financial Information
KPI Information (₹ in Crores)
| Particular | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 21.02 | 35.83 | 31.31 | 0.9 |
| ROCE % | 24.22 | 38.45 | 32.4 | 19.43 |
| Debt / Equity | 1.07 | 1.5 | 2.14 | 3.09 |
| RoNW % | 17.99 | 27.37 | 22.94 | 4.36 |
| PbW | 0 | 0 | 0 | 0 |
| Pat Margin % | 10.38 | 10.09 | 7.66 | 1.29 |
Return Ratio
IPO Reservations
| Category | Shares Offered | Shares Offered % | Max Allotee |
|---|---|---|---|
| Qualified Institutions | 540000 | 29.51 | 0 |
| Non-Institutional | 390000 | 21.31 | 0 |
| BNII | 258000 | 14.1 | 0 |
| SNII | 132000 | 7.21 | 0 |
| Retail Investors | 900000 | 49.18 | 0 |
| Total | 1830000 | 100 | 0 |
Subscription Status ( Thu, 14 May 26 01:45 PM)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutions | 540000 | 97317000 | 180.22x |
| Non-Institutional | 390000 | 648333000 | 1662.39x |
| BNII | 258000 | 518874000 | 2011.14x |
| SNII | 132000 | 129459000 | 980.75x |
| Retail Investors | 900000 | 793038000 | 881.15x |
| Total | 1830000 | 1538688000 | 840.81x |
Subscription figures are updated periodically and may change until issue closing. Data reflects bids placed across exchanges.
Peer Comparision
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Ltd | 10 | 0.00 | 4.10 | 4.10 | 27.37 | 12.38 |
| Mono Pharmacare Ltd | 10 | 7.57 | 1.75 | 1.75 | 9.90 | 17.66 |
| Chandra Bhagat Pharma Ltd | 10 | 28.94 | 1.14 | 1.14 | 2.86 | 39.72 |
Lot Size & Investment Details
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | 258,000.00 |
| Retail (Max) | 2 | 6,000 | 258,000.00 |
| S-HNI (Min) | 3 | 9,000 | 387,000.00 |
| S-HNI (Max) | 7 | 21,000 | 903,000.00 |
| B-HNI (Min) | 8 | 24,000 | 1,032,000.00 |
Registrar
Bigshare Services Pvt Ltd
91-22-6263 8200
investor@bigshareonline.com
https://www.bigshareonline.com
Book Running Lead Managers
- Cumulative Capital Private Limited
RHP Document
DRHP Document
Anchor Investors
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Goldline Pharmaceutical IPO is a Book-building IPO worth ₹12 crores. The price band is ₹41 to 43 per share. The IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026. It will be listed on BSE and NSE. Bigshare Services Pvt Ltd is the registrar.
The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026
Goldline Pharmaceutical IPO Price Band is ₹41 to 43.
Goldline Pharmaceutical IPO lot size is 3000, and the minimum amount required for application is ₹258000.
The minimum investment for Goldline Pharmaceutical IPO is approximately ₹258000 based on the upper price band.
To apply for the Goldline Pharmaceutical IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Thu, May 14, 2026. After submission, funds are blocked until the basis of allotment of Goldline Pharmaceutical IPO is finalised.
Goldline Pharmaceutical IPO issue size is ₹12 crores.
Goldline Pharmaceutical IPO allotment date is Sat, Jun 27, 2026.
The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website for IPO allotment status, refund processing, and other queries related to Goldline Pharmaceutical IPO through their official website or helpline.
The Goldline Pharmaceutical IPO GMP (Grey Market Premium) is ₹15 as of Tue, May 19, 2026. Based on the upper price band of ₹43 per share, the estimated Goldline Pharmaceutical IPO listing price is ₹58, indicating a potential listing gain of approximately 31% over the issue price.